Sinovac Biotech Ltd. (SVA)
NASDAQ: SVA
· Real-Time Price · USD
6.47
0.00 (0.00%)
At close: Feb 11, 2025, 6:18 AM
Sinovac Biotech Revenue Breakdown
| Period Ending | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|
| Enterovirus71 Vaccines Revenue | 149.22M | 162.54M |
| Enterovirus71 Vaccines Revenue Growth | -8.19% | n/a |
| Inactivated Hepatitis Vaccines Revenue | 57.95M | 63.43M |
| Inactivated Hepatitis Vaccines Revenue Growth | -8.63% | n/a |
| Influenza Vaccines Revenue | 19.14M | 2.03M |
| Influenza Vaccines Revenue Growth | +844.03% | n/a |
| Mumps Vaccines Revenue | 19.73M | 1.66M |
| Mumps Vaccines Revenue Growth | +1089.39% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2022 |
|---|---|
| Outside Mainland China Revenue | 375.99M |
| Outside Mainland China Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2023 | Jun 30, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 176.93M | 231.43M | 671.12M | 156.69M | 432.04M | 162.1M | 83.05M | 47.23M | 29.79M | 16.46M | 33.3M | 34.4M | 30.19M | 23.58M | 40.7M | 28.48M | 44.5M | 23.33M | 51.05M | 37.25M | 15.24M | 12.28M | 8.26M | 6.2M | 11.26M | 9.96M | 9.01M | 6.81M |
| Selling, General, and Administrative Revenue Growth | -23.55% | -65.52% | +328.32% | -63.73% | +166.53% | +95.18% | +75.84% | +58.55% | +80.93% | -50.56% | -3.21% | +13.96% | +28.04% | -42.07% | +42.93% | -36.00% | +90.74% | -54.30% | +37.07% | +144.46% | +24.07% | +48.60% | +33.29% | -44.95% | +13.09% | +10.48% | +32.42% | n/a |
| Research and Development Revenue | 193.38M | 151.13M | 257.71M | 184.39M | 101.13M | 53.91M | 2.66M | 25.95M | 14.45M | 5.69M | 7.76M | 5.66M | 6.35M | 4.49M | 7.14M | 4.69M | 5.88M | 4.19M | 11.71M | 8.78M | 3.58M | 4.22M | 2.78M | 2.07M | 2.84M | 2.21M | 2.21M | 2.2M |
| Research and Development Revenue Growth | +27.96% | -41.36% | +39.76% | +82.34% | +87.59% | +1925.97% | -89.75% | +79.55% | +153.89% | -26.62% | +37.14% | -10.89% | +41.35% | -37.14% | +52.31% | -20.28% | +40.43% | -64.22% | +33.39% | +145.29% | -15.15% | +51.67% | +34.35% | -27.19% | +28.35% | +0.09% | +0.73% | n/a |